Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

JS Carew, FJ Giles, ST Nawrocki - Cancer letters, 2008 - Elsevier
Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene
expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation …

Epigenomics and breast cancer

PK Lo, S Sukumar - Pharmacogenomics, 2008 - Taylor & Francis
Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene
function. Recent progress in the knowledge of epigenomics has had a profound impact on …

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.

S Shankar, RK Srivastava - Advances in experimental medicine and …, 2008 - europepmc.org
Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

JH Park, SH Kim, MC Choi, J Lee, DY Oh, SA Im… - Biochemical and …, 2008 - Elsevier
Vascular endothelial growth factor receptors (VEGFRs) perform pivotal roles in both tumor
growth and angiogenesis. In this study, we report that histone deacetylase inhibitors (HDIs) …

Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma

CL Dalgard, KR Van Quill, JM O'Brien - Clinical Cancer Research, 2008 - AACR
Purpose: To evaluate the potential utility of histone deacetylase inhibitors (HDACi) for
treatment of retinoblastoma (RB). Experimental Design: Growth-inhibitory effects of HDACi …

[HTML][HTML] Heat shock protein 90 inhibition in lung cancer

T Shimamura, GI Shapiro - Journal of thoracic oncology, 2008 - Elsevier
The heat shock protein 90 (Hsp90) chaperone is required for the conformational maturation
and stability of multiple oncogenic kinases that drive signal transduction and proliferation of …

[HTML][HTML] Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

L Nolan, PWM Johnson, A Ganesan, G Packham… - British journal of …, 2008 - nature.com
Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing.
This review highlights the promising data for their combination with a wide range of …

Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of …

JS You, JK Kang, EK Lee, JC Lee, SH Lee, YJ Jeon… - Oncogene, 2008 - nature.com
Dysregulation of DNA methyltransferase (DNMT) 1 expression is associated with cellular
transformation, and inhibition of DNMT1 exerts antitumorigenic effects. Here, we report that …

Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling

X Yi, W Wei, SY Wang, ZY Du, YJ Xu, XD Yu - Biochemical Pharmacology, 2008 - Elsevier
Estrogen receptor α (ERα) plays an important role in the development and progression of
breast cancer, and recent studies showed that ERα expression is associated with resistance …

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

JH Park, HS Jong, SG Kim, Y Jung, KW Lee… - Journal of molecular …, 2008 - Springer
The molecular basis of the antitumor selectivity of histone deacetylase inhibitors (HDIs)
remains unclear. Centrosomal Aurora-A kinase regulates chromosomal segregation during …